Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended dose of CPX-351 for use
in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the
safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of
antitumor activity will also be determined.